RxDoctor Payments Data

Jason Morda, MD

Cardiovascular Disease · Alexandria, VANPI 1043338221

Payments from drug & device makers

$5,113in general payments, 2019–2025

Across 36 payments — averaging $142.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Abbott$926
  • Novartis$464
  • Cvrx, Inc.$439
  • E.r. Squibb & Sons, L.L.C.$339
  • Amgen$179
  • plus $828 from 8 others

What the payments were for

  • Travel & lodging$1,36927%
  • Food & beverage$3,74473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,113 in reported general payments places this provider in the 70th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$271,874
Medicare patients
1,726
Services billed
3,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban320$425,643
EntrestoSacubitril/Valsartan102$154,704
XareltoRivaroxaban120$137,841
JardianceEmpagliflozin84$86,585
FarxigaDapagliflozin Propanediol42$58,941
Repatha SureclickEvolocumab27$36,381
MultaqDronedarone Hcl20$32,567
NexlizetBempedoic Acid/Ezetimibe14$15,008
Carvedilol ErCarvedilol Phosphate30$11,909
Dabigatran EtexilateDabigatran Etexilate Mesylate40$11,283
Valsartan273$8,414
Propafenone Hcl ErPropafenone Hcl22$5,380
Metoprolol Succinate299$4,875
Irbesartan136$4,178
Rosuvastatin Calcium264$4,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$464$154,704102 claims
Johnson & JohnsonXarelto$88$137,841120 claims
Boehringer IngelheimJardiance$107$86,58584 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →